We are pleased to announce that with the help of a few HHV-6 specialists, especially Prof. Louis Flamand from Canada, we have generated the monoclonal antibody DR-7.
Q & A with Dr. Bhupesh Prusty and Professor Thomas Rudel
Dr. Bhupesh Prusty and Professor Thomas Rudel from Biozentrum University have published several articles on the phenomenon of ciHHV-6 activation including a study on the interaction between Chlamydia infection and ciHHV-6. We interviewed them about the implications of these findings, their current studies, and what lies ahead for this team in the field of ciHHV-6 research.
ciHHV-6 low in Quebec children with ALL and absent in controls
The frequency of ciHHV-6 in the Province of Quebec (Canada) appears to be lower than that observed in US and UK.
REVIEW: Important differences between the HHV-6A and HHV-6B viruses
An international group of experts summarize the significant differences between the two viruses.
Chimerix “SUPPRESS” trial to be largest ever for HHV-6 treatment
Chimerix “SUPPRESS” trial to be largest study ever conducted for treatment of HHV-6 infection
HHV-6 as a trigger of autoimmune disease?
Researchers discuss the potential mechanisms by which HHV-6A/B may contribute to autoimmune disease
Another fatal case of HHV-6 myocarditis in an immunocompetent adult
Group suggests cardiac magnetic resonance (CMR) may be an important tool for the timely diagnosis
French dermatologists call for antiviral therapy in DRESS
French panel of experts has proposed that DRESS patients be treated with antivirals and/or immunoglobulins.
Human herpesvirus replication is activated by apoptosis
A group led by Steven Zeichner has published evidence that suggests the replication of all human herpesviruses can be activated by apoptosis.
Does HHV-6 cause thyroiditis and autoimmunity in patients with drug hypersensitivity?
Case report describes two cases of DRESS related thyroiditis with very high levels of HHV-6 reactivation that go on to develop autoimmunity.
Humanized mouse model demonstrates HHV-6A infection can cause significant immune dysfunction
Could treatment of HHV-6A co-infections slow AIDS progression?
Preliminary evidence indicates HHV-6B may be involved in the sporadic development of adenomatous GI Polyps
A group from Finland’s Helsinki University Hospital has published preliminary evidence to suggest HHV-6B may be involved in the development of adenomatous gastrointestinal polyps
MCP-1 found elevated in the CSF of patients with HHV-6B encephalopathy
Japanese group identifies several cytokine and chemokine responses associated with HHV-6B encephalopathy.
Study shows HHV-6 reactivation is disproportionately elevated among patients with autoimmune connective tissue disease
New study from Italy indicates that HHV-6 reactivation is selectively increased among patients suffering from autoimmune connective tissue diseases (ACTD).
HHV-6B infection promotes unique pro-inflammatory effects tied to neurocognitive decline and artherosclerosis
HHV-6A and HHV-6B each express distinct chemokines that are uniquely capable of activating key inflammatory cytokines.